American Century Companies Inc. Invests $711,000 in Integral Ad Science Holding Corp. $IAS

Key Points

• American Century Companies Inc. acquired 88,256 shares of Integral Ad Science Holding Corp., valued at approximately $711,000, establishing a new position in the company.
• Integral Ad Science recently received updates from analysts, including a upgrade from a "hold" to a "buy" rating by Wall Street Zen and an average price target of $13.55.
• Integral Ad Science reported earnings of $0.07 EPS, exceeding analysts' expectations, with revenue of $149.20 million for the quarter.

American Century Companies Inc. purchased a new stake in Integral Ad Science Holding Corp. (NASDAQ:IAS - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 88,256 shares of the company's stock, valued at approximately $711,000. American Century Companies Inc. owned 0.05% of Integral Ad Science as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Integral Ad Science by 0.5% during the first quarter. Vanguard Group Inc. now owns 9,090,229 shares of the company's stock valued at $73,267,000 after buying an additional 41,683 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of Integral Ad Science by 12.7% during the 1st quarter. Aberdeen Group plc now owns 1,994,980 shares of the company's stock valued at $16,080,000 after purchasing an additional 224,153 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Integral Ad Science by 0.8% in the fourth quarter. Nuveen Asset Management LLC now owns 1,920,523 shares of the company's stock worth $20,050,000 after buying an additional 15,432 shares during the last quarter. Nuveen LLC bought a new stake in shares of Integral Ad Science during the 1st quarter worth $10,897,000. Finally, Invenomic Capital Management LP increased its stake in shares of Integral Ad Science by 52.9% in the fourth quarter. Invenomic Capital Management LP now owns 895,061 shares of the company's stock worth $9,344,000 after purchasing an additional 309,752 shares during the period. 95.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Integral Ad Science news, CEO Lisa Utzschneider sold 14,904 shares of the firm's stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $8.31, for a total transaction of $123,852.24. Following the transaction, the chief executive officer owned 379,316 shares in the company, valued at $3,152,115.96. This trade represents a 3.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 35,073 shares of company stock worth $289,641. 2.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

IAS has been the topic of a number of analyst reports. Barclays upped their target price on shares of Integral Ad Science from $9.00 to $10.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Wall Street Zen raised Integral Ad Science from a "hold" rating to a "buy" rating in a report on Sunday, August 10th. Stifel Nicolaus lifted their target price on Integral Ad Science from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. Finally, Raymond James Financial lowered their price target on shares of Integral Ad Science from $13.00 to $11.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.55.

Integral Ad Science Stock Performance

IAS traded down $0.09 on Wednesday, hitting $8.46. 1,313,743 shares of the company were exchanged, compared to its average volume of 759,417. The stock's fifty day moving average is $8.56 and its 200-day moving average is $8.28. The company has a market cap of $1.41 billion, a PE ratio of 24.88, a PEG ratio of 1.22 and a beta of 1.57. Integral Ad Science Holding Corp. has a 12 month low of $6.26 and a 12 month high of $13.62.

Integral Ad Science (NASDAQ:IAS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.03. The business had revenue of $149.20 million for the quarter, compared to analyst estimates of $143.02 million. Integral Ad Science had a return on equity of 5.00% and a net margin of 9.79%. Integral Ad Science has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts expect that Integral Ad Science Holding Corp. will post 0.26 EPS for the current fiscal year.

Integral Ad Science Company Profile

Integral Ad Science Holding Corp. operates as a digital advertising verification company in the United States, the United Kingdom, France, Ireland, Germany, Italy, Singapore, Australia, Japan, India, and the Nordics. The company provides IAS Signal, a cloud-based technology platform that offers return on ad spend needs; and deliver independent measurement and verification of digital advertising across devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video.